High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.

@article{Urbonaviciute2011HighmobilityGB,
  title={High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.},
  author={Vilma Urbonaviciute and Reinhard Edmund Voll},
  journal={Journal of internal medicine},
  year={2011},
  volume={270 4},
  pages={309-18}
}
High-mobility group box 1 (HMGB1) protein is a nuclear DNA-binding protein, which functions as an alarmin when released from cells. Recent studies implicate extracellular HMGB1 in the pathogenesis of systemic lupus erythematosus (SLE), a prototypical autoimmune disease characterized by the formation of multiple autoantibodies, especially those directed against nucleosomes and double-stranded (ds)DNA. Elevated concentrations of HMGB1 are observed in sera as well as in skin lesions of patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Studies on Lupus Nephritis

View 4 Excerpts
Highly Influenced

Post-translational modifications of high mobility group box 1 and cancer.

American journal of translational research • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 70 references

HMGB 1 IsaTherapeuticTarget forSterile Inflammation and Infection

P Scaffidi, T Misteli, ME Bianchi
Annu Rev Immunol • 2011

Participationof thereceptor for advanced glycation end products in efferocytosis

BanerjeeS FriggeriA
J Immunol • 2011

The Association for the Publication of the

V. Urbonaviciute, R. E. Voll
Journal of Internal Medicine Journal of Internal Medicine • 2011

AJ.HMGB1and RAGE in inflammation and cancer.AnnuRev Immunol

SimsGP, RoweDC, ST Rietdijk, R Herbst, Coyle
2010

Similar Papers

Loading similar papers…